Sept 10 (Reuters) - The market for weight-loss

treatments is expected to see 16 new drugs vying for a slice of

the lucrative business currently dominated by Novo Nordisk

and Eli Lilly ( LLY ), according to estimates from

analysts at Morningstar and Pitchbook.

In a joint report published on Monday, analysts estimated

the market for obesity treatments could expand to $200 billion

by 2031. The 16 drugs could launch by 2029, with roughly $70

billion of the GLP-1 market coming from these new challengers.

WHY IT'S IMPORTANT

Surging demand for Novo's Wegovy and Lilly's Zepbound has

sparked interest among competitors to test their own weight-loss

treatments. Companies such as Amgen ( AMGN ) and Pfizer ( PFE )

are currently testing their drug candidates in clinical trials.

These developments come amid criticism from lawmakers over

the high costs associated with these medications. The new

entrants, however, are expected to drive down prices as they vie

for market share, according to the report.

CONTEXT

The potential new treatments include those from Boehringer

Ingelheim and Zealand Pharma, along with competitors

from Roche, Amgen ( AMGN ) and Pfizer ( PFE ), according

to the report, provided that the drugs clear clinical trials.

Other entrants include those by Structure Therapeutics ( GPCR )

, Viking Therapeutics ( VKTX ) and Altimmune ( ALT ),

along with next-generation drugs by Novo and Lilly.

Analysts, last year, had forecast the obesity market would

be $170 billion by 2031, but have recently raised their

estimates, partly due to anticipated higher diabetes market

penetration.

The report projects 41% individuals with diabetes and nearly

one-quarter of nondiabetic obesity patients will be on a GLP-1

drug by 2031.

WHAT'S NEXT

Analysts expect significant acquisitions by major

pharmaceutical companies in the obesity sector over the next 18

months, targeting smaller companies specializing in obesity drug

development.

Potential acquisition targets include firms such as

Structure, Viking and Altimmune ( ALT ).

Private companies such as NodThera, Corteria and Diasome

have a higher-than-50% chance of being acquired, according to

PitchBook data.